Chronic Limb-Threatening Ischemia clinical trials at UCSF
2 in progress, 1 open to eligible people
Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers
open to eligible people ages 18 years and up
This study will assess the safety and efficacy of intramuscular injection of AMG0001 (hepatocyte growth factor [HGF] plasmid) to improve ulcer healing and perfusion in patients with peripheral artery disease.
San Francisco, California and other locations
The PROMISE II Trial, Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
Sorry, in progress, not accepting new patients
The LimFlow System is intended for endovascular, minimally invasive procedures in patients who have a clinical diagnosis of chronic limb-threatening ischemia and who have been determined to have no surgical or endovascular treatment option (i.e., "no option").
San Francisco, California and other locations
Our lead scientists for Chronic Limb-Threatening Ischemia research studies include Michael S Conte, MD.
Last updated: